FLT3 and acute myeloid leukemia: Viability assay confirmed that treatment with FLT3 inhibitors decreased cell viability in AML PBMCs by about 17–33%, however, treatment with FLT3 inhibitors decreased cell viability of MV4-11 cells (an AML cell line that carries the FLT3-ITD mutation) by more than 50% (Fig. 3C).